CoChat
Sign Up
Cited by 148Pharmaceutical Practices and Patient OutcomesOpioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The epidemiology of long-term benzodiazepine use

Neutel, C. Ineke·2005·International Review of Psychiatry
DOI 10.1080/09540260500071863
Open this paper in CoChat — free account

Abstract

Recommendations for benzodiazepine (BZD) use suggest durations of no more than a few weeks, but studies report use for months, years, or even decades. This article examines the who (who are long-term users), why (why do they use BZD), what (what are patterns of long-term use) and how (how do they compare to all BZD users). The study population is from the National Population Health Survey in Canada which interviewed respondents four times at two-year intervals, asking about specific drugs use as well as demographic, lifestyle and health-related questions. Long-term BZD use was defined as BZD use for two successive cycles. Four percent of the Canadian population used BZD at any one time, half of whom also reported use in the previous cycle. Benzodiazepine users were more likely to be female, elderly, smokers, to prefer speaking a language other than English, to have insurance coverage for medication, and to have completed high school education. Almost none of these determinants predicted long-term use. Persons reporting BZD use in 2000 had an odds ratio (OR) of 38.6 for also using BZD in 1998, were more likely to use antidepressants (OR=8.5) and suffer from conditions such as poor health, stress, and pain. Most of these determinants had no association with long-term use or if they did at a considerably lower OR. Of the 395 BZD users in 2000, almost 48.4% also used BZD in the previous cycle and 17% in all three previous cycles. Benzodiazepine use in any previous cycle made BZD use in 2000 more likely, with use determined by how recent and the frequency of reported use, culminating in a very high OR of 83.3 for use in all three previous cycles. Continued use for any of the individual BZD tended to be largely for the same BZD. We conclude that: (1) the overriding determinant for BZD use was that of previous use; and (2) long-term use was not determined by the same factors as overall use, which is significant in developing approaches to dealing with long-term BZD use.

Overview

Integrity signals

Registry

Crossref · 10.1080/09540260500071863

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 10

  1. Barnas C., 1991, investigation of benzo-diazepine consumers among pharmacy customers. Psycho-pharmacology (Berl.), 103, 233
  2. CPS (2003). Compendium of Pharmaceutical and Specialities. 38th edition. Canadian Pharmaceutical Association of Canada, Ottawa, Canada.
  3. Damestoy N., 1999, Canadian Medical Association Journal, 161, 143
  4. Gales B. J., 1995, Annals of Pharmacotherapy, 29, 534
  5. Holbrook A. M., 2000, Canadian Medical Association Journal, 62, 216
  6. Kallin K., 2004, Journal of Family Practice, 53, 41
  7. Lenze E. J., 2003, Central Nervous System Spectrum, 8, 6
  8. Nelson J., 1999, Canadian Journal of Clinical Pharmacology, 6, 69
  9. Pimlott N. J., 2003, Canadian Medical Association Journal, 168, 835
  10. Walop W., 2002, Canadian Journal of Clinical Pharmacology, 9, 64

Cited by

Sorted by citations

See all 148

Related

Metadata

Authors
Neutel, C. I.
Affiliations
Public Health Agency of Canada (CA)
Corresponding author
Neutel, C. Ineke
Venue
International Review of Psychiatry
Publisher
Informa UK Limited
Published
2005-01
Volume
17
Issue
3
Pages
189-197
ISSN
  • 0954-0261 (ISSN-L)
  • 1369-1627
DOI
10.1080/09540260500071863
OpenAlex
W2131124552
Cited by
148
References
45
Citations by year
2025: 3 · 2024: 2 · 2023: 4 · 2022: 10 · 2021: 3 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 8 · 2015: 7 · 2014: 7 · 2013: 12 · 2012: 13
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • International Review of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
long-term benzodiazepine use, antidepressant use, chronic pain, stress, drug use trends, National Population Health Survey
MeSH terms
Mental Disorders, Benzodiazepines, Humans, Drug Prescriptions, Time, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review